全文获取类型
收费全文 | 4089篇 |
免费 | 261篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 85篇 |
妇产科学 | 117篇 |
基础医学 | 554篇 |
口腔科学 | 131篇 |
临床医学 | 411篇 |
内科学 | 1071篇 |
皮肤病学 | 60篇 |
神经病学 | 338篇 |
特种医学 | 162篇 |
外科学 | 628篇 |
综合类 | 33篇 |
预防医学 | 297篇 |
眼科学 | 54篇 |
药学 | 198篇 |
中国医学 | 1篇 |
肿瘤学 | 193篇 |
出版年
2023年 | 29篇 |
2022年 | 26篇 |
2021年 | 58篇 |
2020年 | 57篇 |
2019年 | 85篇 |
2018年 | 97篇 |
2017年 | 65篇 |
2016年 | 79篇 |
2015年 | 93篇 |
2014年 | 87篇 |
2013年 | 165篇 |
2012年 | 220篇 |
2011年 | 234篇 |
2010年 | 113篇 |
2009年 | 112篇 |
2008年 | 191篇 |
2007年 | 198篇 |
2006年 | 190篇 |
2005年 | 153篇 |
2004年 | 170篇 |
2003年 | 144篇 |
2002年 | 138篇 |
2001年 | 108篇 |
2000年 | 132篇 |
1999年 | 114篇 |
1998年 | 42篇 |
1997年 | 31篇 |
1996年 | 40篇 |
1995年 | 33篇 |
1994年 | 38篇 |
1993年 | 35篇 |
1992年 | 81篇 |
1991年 | 73篇 |
1990年 | 84篇 |
1989年 | 82篇 |
1988年 | 75篇 |
1987年 | 77篇 |
1986年 | 68篇 |
1985年 | 51篇 |
1984年 | 55篇 |
1983年 | 48篇 |
1982年 | 27篇 |
1981年 | 31篇 |
1980年 | 22篇 |
1979年 | 33篇 |
1977年 | 22篇 |
1975年 | 30篇 |
1974年 | 36篇 |
1973年 | 34篇 |
1970年 | 21篇 |
排序方式: 共有4353条查询结果,搜索用时 15 毫秒
1.
In recent years, there has been an increased focus on patient involvement in treatment planning in the health care system. To reduce the risk of the clinician moving towards paternalism, various methods have been introduced—shared decision making, among others. The goal of shared decision making is for the clinician and patient to share available evidence on the best treatment and to raise awareness on the needs and preferences of the patient as to make a genuinely informed choice. However, in the present article, we discuss to which degree paternalism can be avoided in light of the clinician's role as an authority with certain knowledge and expertise. Through the philosophical theory of reasons‐responsiveness, we discuss to which extend free will and control applies to the patient. Through theoretical analysis, we come to suggest that the clinician has a role as an ally rather than manipulator. 相似文献
2.
Low myocardial glucose uptake in Turner syndrome is unaffected by growth hormone: a randomized,placebo‐controlled FDG‐PET study 下载免费PDF全文
3.
K Thomsen B J Riis J S Johansen C Christiansen P R?dbro 《Gynecological endocrinology》1987,1(2):169-175
Bone turnover before and after withdrawal of estrogen/gestagen treatment was studied in a randomized trial with 110 healthy female volunteers, who had passed a natural menopause 6 months to 3 years before the start of the study. Urinary excretion of intravenously injected 99m-technetium diphosphonate was measured as an index of bone turnover; plasma bone Gla protein and serum alkaline phosphatase were measured as indices of bone formation; and fasting urinary excretion of hydroxyproline and calcium were measured as estimates of bone resorption. During 2 years of hormone treatment, all variables decreased highly significantly (p less than 0.001) to a constant low level. Three months after withdrawal all variables increased highly significantly (p less than 0.001) towards, but not above, pretreatment and placebo levels. We conclude that withdrawal of estrogen/gestagen replacement therapy in postmenopausal women increases bone turnover, but not in excess of pretreatment values. This indicates that bone loss (after withdrawal) is similar to that seen in the placebo group and that a rebound phenomenon is unlikely. 相似文献
4.
5.
Jens O L J?rgensen Louise M?ller Morten Krag Nils Billestrup Jens S Christiansen 《Endocrinology & Metabolism Clinics of North America》2007,36(1):75-87
This article focuses on in vivo data from tests performed in normal subjects and in patients who had abnormal growth hormone (GH) status. Experimental data in human subjects demonstrate that GH acutely inhibits glucose disposal in skeletal muscle. At the same time GH stimulates the turnover and oxidation of free fatty acid (FFA), and experimental evidence suggests a causal link between elevated FFA levels and insulin resistance in skeletal muscle. Observational data in GH-deficient adults do not indicate that GH replacement is associated with significant impairment of glucose tolerance, but it is recommended that overdosing be avoided and glycemic control be monitored. 相似文献
6.
PURPOSE: Currently, no drug treatment is available for strengthening underacting extraocular muscles (EOM) in strabismus. We showed previously that single injections of insulin-like growth factor (IGF-1) result in significant but short-term increases in muscle force generation. This study examined the effects of sustained release of IGF-1 on force generation in rabbit superior rectus muscles. METHODS: In adult rabbits, slow-release pellets containing IGF-1 were implanted on the global side of one superior rectus muscle. After 1 week, or 1, 2, 3, or 6 months, treated and control muscles were examined for force generation using an in vitro physiology apparatus. All muscles were prepared for histology and mean myofiber cross-sectional areas were determined. RESULTS: One and 3 months after pellet implantation, treated muscles generated significantly greater force than contralateral control muscles, whereas at 2 months, no significant difference was found. Force per cross-sectional area (mN/cm(2)) at 3 months also increased significantly in the treated muscles. Mean muscle cross-sectional area increased significantly after 1, 2, and 3 months of sustained exposure to IGF-1 compared with controls. After an additional 3 months without IGF-1 exposure, mean cross-sectional areas were significantly greater than controls but significantly reduced compared with areas at 1, 2, and 3 months. CONCLUSIONS: IGF-1 appears to be highly effective in increasing muscle force generation. Because slow release of IGF-1 results in sustained increases in EOM force generation, it may be a potentially useful alternative to surgical resection procedures because it avoids many of the potential long-term biomechanical hazards of resection surgery. 相似文献
7.
8.
9.
Morten A Karsdal Thomas J Martin Jens Bollerslev Claus Christiansen Kim Henriksen 《Journal of bone and mineral research》2007,22(4):487-494
Some osteopetrotic mutations lead to low resorption, increased numbers of osteoclasts, and increased bone formation, whereas other osteopetrotic mutations lead to low resorption, low numbers of osteoclasts, and decreased bone formation. Elaborating on these findings, we discuss the possibility that osteoclasts are the source of anabolic signals for osteoblasts. In normal healthy individuals, bone formation is coupled to bone resorption in a tight equilibrium. When this delicate balance is disturbed, the net result is pathological situations, such as osteopetrosis or osteoporosis. Human osteopetrosis, caused by mutations in proteins involved in the acidification of the resorption lacuna (ClC-7 or the a3-V-ATPase), is characterized by decreased resorption in face of normal or even increased bone formation. Mouse mutations leading to ablation of osteoclasts (e.g., loss of macrophage-colony stimulating factor [M-CSF] or c-fos) lead to secondary negative effects on bone formation, in contrast to mutations where bone resorption is abrogated with sustained osteoclast numbers, such as the c-src mice. These data indicate a central role for osteoclasts, and not necessarily their resorptive activity, in the control of bone formation. In this review, we consider the balance between bone resorption and bone formation, reviewing novel data that have shown that this principle is more complex than originally thought. We highlight the distinct possibility that osteoclast function can be divided into two more or less separate functions, namely bone resorption and stimulation of bone formation. Finally, we describe the likely possibility that bone resorption can be attenuated pharmacologically without the undesirable reduction in bone formation. 相似文献
10.
Stefan Christiansen Rüdiger Autschbach 《European journal of cardio-thoracic surgery》2006,30(4):611-616
Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability. 相似文献